Jacobson Pharma Corporation Limited
雅各臣科研製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
Stock Code : 2633

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

FINANCIAL HIGHLIGHTS

- The revenue for the six months ended 30 September 2022 amounted to approximately HK$817.4 million, representing an increase of about 8.9% as compared to that of approximately HK$750.4 million for the corresponding period of 2021.

- Profit from operations for the same period amounted to approximately HK$201.0 million, representing an increase of about 71.9% as compared to that of approximately HK$116.9 million for the corresponding period of 2021.

- Profit for the same period amounted to approximately HK$147.4 million, representing an increase of about 77.8% as compared to that of approximately HK$82.9 million for the corresponding period of 2021.

- The Board declared the payment of an interim dividend for the six months ended 30 September 2022 of HK2.8 cents per ordinary share for the total amount of approximately HK$54.2 million (six months ended 30 September 2021: HK1.2 cents per ordinary share).

The Board is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 September 2022, together with the comparative figures for the corresponding period of 2021 as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 September 2022 – unaudited

		Six months ended 30 September	
		2022	2021
	Note	***HK$'000***	*HK$'000*
Revenue	*4*	**817,353**	750,413
Cost of sales		**(476,924)**	(477,571)
Gross profit		**340,429**	272,842
Other net income	*5*	**48,955**	26,598
Selling and distribution expenses		**(92,082)**	(88,591)
Administrative and other operating expenses		**(96,262)**	(93,978)
Profit from operations		**201,040**	116,871
Finance costs	*6(A)*	**(22,254)**	(12,865)
Share of losses of associates		**(1,499)**	(1,815)
Share of losses of joint ventures		**(519)**	(285)
Profit before taxation	*6*	**176,768**	101,906
Income tax	*7*	**(29,400)**	(19,047)
Profit for the period		**147,368**	82,859

	Note	Six months ended 30 September 2022 HK$'000	2021 HK$'000
Other comprehensive income for the period			
Item that will not be reclassified subsequently to profit or loss, net of nil tax:			
Revaluation of financial assets at fair value through other comprehensive income		**(29,222)**	(7,334)
Item that may be reclassified subsequently to profit or loss, net of nil tax:			
Exchange differences on translation of financial statements of operations outside Hong Kong		**(3,998)**	(51)
Other comprehensive income for the period		**(33,220)**	(7,385)
Total comprehensive income for the period		**114,148**	75,474
Profit attributable to:			
Equity shareholders of the Company		**136,192**	80,039
Non-controlling interests		**11,176**	2,820
Total profit for the period		**147,368**	82,859
Total comprehensive income attributable to:			
Equity shareholders of the Company		**102,972**	72,654
Non-controlling interests		**11,176**	2,820
Total comprehensive income for the period		**114,148**	75,474
		HK cents	*HK cents*
Earnings per share	*8*		
Basic and diluted		**7.10**	4.18

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
At 30 September 2022 – unaudited

	Note	**As at 30 September 2022** *HK$'000*	As at 31 March 2022 *HK$'000*
Non-current assets			
Investment properties		**230,472**	230,472
Property, plant and equipment		**1,463,920**	1,503,773
Intangible assets		**1,281,775**	1,303,177
Interests in associates		**52,430**	53,929
Interests in joint ventures		**3,815**	4,334
Other non-current assets		**62,762**	58,688
Other financial assets		**383,544**	412,766
Deferred tax assets		**10,019**	10,156
		3,488,737	3,577,295
Current assets			
Inventories		**376,926**	314,557
Trade and other receivables	*10*	**326,333**	380,546
Current tax recoverable		**3,548**	4,489
Cash and cash equivalents		**860,409**	478,653
		1,567,216	1,178,245
Current liabilities			
Trade and other payables	*11*	**243,465**	159,411
Bank loans		**60,000**	612,178
Lease liabilities		**38,285**	33,970
Current tax payable		**43,048**	20,825
		384,798	826,384
Net current assets		**1,182,418**	351,861
Total assets less current liabilities		**4,671,155**	3,929,156

	Note	As at 30 September 2022 HK$'000	As at 31 March 2022 HK$'000
Non-current liabilities			
Bank loans		**1,424,660**	729,472
Lease liabilities		**34,375**	34,319
Deferred tax liabilities		**207,935**	207,400
		1,666,970	971,191
NET ASSETS		**3,004,185**	2,957,965
CAPITAL AND RESERVES			
Share capital	*12*	**19,029**	19,157
Reserves		**2,508,609**	2,472,159
Total equity attributable to equity shareholders of the Company		**2,527,638**	2,491,316
Non-controlling interests		**476,547**	466,649
TOTAL EQUITY		**3,004,185**	2,957,965

NOTES

1 CORPORATE INFORMATION

Jacobson Pharma Corporation Limited is an exempted company with limited liability incorporated in the Cayman Islands. The Company is an investment holding company. The Company and its subsidiaries are principally engaged in the development, production, marketing and sale of generic drugs and branded healthcare products. The Company's shares were listed on the Main Board on 21 September 2016.

2 BASIS OF PREPARATION

The interim financial results set out in this announcement do not constitute the Group's interim financial report for the six months ended 30 September 2022 but are extracted from that interim financial report.

The interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Stock Exchange, including compliance with Hong Kong Accounting Standard ("**HKAS**") 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the consolidated financial statements for the year ended 31 March 2022, except for the accounting policy changes that are expected to be reflected in the consolidated financial statements for the year ending 31 March 2023. Details of any changes in accounting policies are set out in note 3.

3 CHANGES IN ACCOUNTING POLICIES

The Group has applied the following amendments to Hong Kong Financial Reporting Standards ("**HKFRSs**") issued by the HKICPA for the current accounting period:

- Amendments to HKAS 16, *Property, plant and equipment: Proceeds before intended use*

- Amendments to HKAS 37, *Provisions, contingent liabilities and contingent assets: Onerous contracts — cost of fulfilling a contract*

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period. Impacts of the adoption of the amended HKFRSs are discussed below:

Amendments to HKAS 16, *Property, plant and equipment: Proceeds before intended use*

The amendments prohibit an entity from deducting the proceeds from selling items produced before that asset is available for use from the cost of an item of property, plant and equipment. Instead, the sales proceeds and the related costs should be included in profit and loss. The amendments do not have a material impact on the financial statements as the Group does not sell items produced before an item of property, plant and equipment is available for use.

Amendments to HKAS 37, *Provisions, contingent liabilities and contingent assets: Onerous contracts — cost of fulfilling a contract*

The amendments clarify that for the purpose of assessing whether a contract is onerous, the cost of fulfilling the contract includes both the incremental costs of fulfilling that contract and an allocation of other costs that relate directly to fulfilling contracts.

Previously, the Group included only incremental costs when determining whether a contract was onerous. In accordance with the transitional provisions, the Group has applied the new accounting policy to contracts for which it has not yet fulfilled all its obligations at 1 April 2022, and has concluded that none of them is onerous.

4 REVENUE AND SEGMENT REPORTING

(A) Revenue

The principal activities of the Group are development, production, marketing and sale of generic drugs and branded healthcare products. All the revenue for the six months ended 30 September 2022 and 2021 was recognised in accordance with HKFRS 15, *Revenue from contracts with customers.*

Revenue represents the sales value of goods supplied to customers less returns and sales rebates and is after deduction of any trade discounts.

(B) Segment reporting

The Group manages its businesses by divisions, which are organised by business lines. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has presented the following two reportable segments. No operating segments have been aggregated to form the following reportable segments.

– Generic drugs: this segment develops, manufactures and/or distributes a host of off-patent medicines for various therapeutic use. Currently the activities in this regard are primarily carried out in Hong Kong.

– Branded healthcare: this segment develops, manufactures and/or distributes branded medicines, proprietary Chinese medicines and health and wellness products. Currently the activities in this regard are primarily carried out in Hong Kong.

Revenue and expenses are allocated to the reportable segments with reference to sales generated by those segments and the expenses incurred by those segments or which otherwise arise from the depreciation or amortisation of assets attributable to those segments.

The measure used for reporting segment profit is "adjusted EBITDA" i.e. "adjusted earnings before interest, taxes, depreciation and amortisation", where "interest" is regarded as including interest income and interest expenses and "depreciation and amortisation" is regarded as including impairment losses on non-current assets. To arrive at adjusted EBITDA, the Group's earnings are further adjusted for share of losses of associates, share of losses of joint ventures and non-recurring items not attributable to the operations of individual segments.

Inter-segment sales are priced with reference to prices charged to external parties for similar orders.

Segment assets and liabilities of the Group are not reported to the Group's chief operating decision makers regularly. As a result, reportable assets and liabilities have not been presented in this interim results announcement.

(i) ***Segment revenue and results***

Information regarding the Group's reportable segments as provided to the Group's chief operating decision makers for the purposes of resource allocation and assessment of segment performance for the period is set out below:

	Generic drugs Six months ended 30 September		**Branded healthcare Six months ended 30 September**		**Total Six months ended 30 September**	
	2022	2021	**2022**	2021	**2022**	2021
	HK$'000	*HK$'000*	***HK$'000***	*HK$'000*	***HK$'000***	*HK$'000*
Revenue from external customers recognised at a point in time	**581,891**	562,177	**235,462**	188,236	**817,353**	750,413
Inter-segment revenue	**40**	160	**1,386**	1,136	**1,426**	1,296
Reportable segment revenue	**581,931**	562,337	**236,848**	189,372	**818,779**	751,709
Reportable segment profit (adjusted EBITDA)	**233,780**	162,879	**56,823**	41,085	**290,603**	203,964

(ii) ***Reconciliations of reportable segment revenue and profit or loss***

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
Revenue		
Reportable segment revenue	**818,779**	751,709
Elimination of inter-segment revenue	**(1,426)**	(1,296)
Consolidated revenue	**817,353**	750,413
Profit		
Reportable segment profit	**290,603**	203,964
Elimination of inter-segment profit	**(146)**	(108)
Reportable segment profit derived from Group's external customers	**290,457**	203,856
Interest income from bank deposits and the investments	**3,294**	881
Fair value gain on investment properties	**–**	9,716
Depreciation and amortisation	**(92,711)**	(97,582)
Finance costs	**(22,254)**	(12,865)
Share of losses of associates	**(1,499)**	(1,815)
Share of losses of joint ventures	**(519)**	(285)
Consolidated profit before taxation	**176,768**	101,906

(iii) Geographic information

The following table sets out information about the geographical location of the Group's revenue from external customers. The geographical location of customers is based on the location at which the goods are distributed to distributors or the ultimate customers by the Group or the consignees.

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
Revenue from external customers		
Hong Kong (place of domicile)	**711,319**	676,186
Mainland China	**66,251**	26,811
Macau	**21,616**	33,241
Singapore	**5,507**	5,425
Others	**12,660**	8,750
	817,353	750,413

The following table sets out information about the geographical location of the Group's property, plant and equipment, investment properties, intangible assets, other non-current assets and interests in associates and joint ventures ("**specified non-current assets**"). The geographical location of the specified non-current assets is based on the physical location of the assets, in the case of investment properties, property, plant and equipment and non-current prepayments for property, plant and equipment, the location of the operations to which they are allocated, in the case of intangible assets and non-current prepayments, and the location of operations, in the case of interests in associates and joint ventures.

	As at 30 September 2022	As at 31 March 2022
	HK$'000	*HK$'000*
Specified non-current assets		
Hong Kong (place of domicile)	**2,970,403**	3,025,001
Mainland China	**43,518**	47,981
Macau	**11**	–
Taiwan	**4,879**	4,940
Cambodia	**76,363**	76,451
	3,095,174	3,154,373

(iv) Information about major customers

For the six months ended 30 September 2022, the Group's customer base includes one (six months ended 30 September 2021: one) customer of generic drugs and branded healthcare segments with whom transactions have exceeded 10% of the Group's revenue. Revenue from sales of generic drugs and branded healthcare products to this customer, including sales to entities which are known to the Group to be under common control amounted to approximately HK$296,842,000 (six months ended 30 September 2021: HK$276,346,000).

5 OTHER NET INCOME

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
Commission income	**1,072**	786
Interest income from bank deposits and the investments	**3,294**	881
Net foreign exchange gain/(loss)	**1,023**	(127)
Net loss on disposal of property, plant and equipment and intangible assets	**(804)**	(520)
Fair value gain on investment properties	**–**	9,716
Subcontracting income	**2,992**	4,903
Rental income	**382**	482
Net distribution and logistic service income	**13,774**	8,469
Government grants *(Note)*	**26,639**	–
Others	**583**	2,008
	48,955	26,598

Note: During the six months ended 30 September 2022, the Group successfully applied for funding support from the Employment Support Scheme. The purpose of the funding is to provide financial support to enterprises to retain their employees who would otherwise be made redundant. Under the terms of the grant, the Group is required not to make redundancies during the subsidy period and to spend all the funding on paying wages to the employees.

6 PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
(A) Finance costs		
Interest on bank loans	**21,454**	12,095
Interest on lease liabilities	**800**	770
	22,254	12,865

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
(B) Other items		
Amortisation of intangible assets	**21,778**	22,348
Depreciation		
– owned property, plant and equipment	**49,855**	52,261
– right-of-use assets	**21,078**	22,973
(Reversal)/write–down of inventories	**(6,820)**	2,174

7 INCOME TAX

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
Current tax	**28,994**	19,619
Deferred taxation	**406**	(572)
	29,400	19,047

The provision for Hong Kong Profits Tax is calculated by applying the estimated annual effective tax rate of 16.5% (six months ended 30 September 2021: 16.5%) to the six months ended 30 September 2022. Taxation for overseas subsidiaries is similarly calculated using the estimated annual effective rates of taxation that are expected to be applicable in the relevant jurisdictions.

8 EARNINGS PER SHARE

(A) Basic earnings per share

The calculation of basic earnings per share is based on the profit attributable to equity shareholders of the Company of HK$136,192,000 for the six months ended 30 September 2022 (six months ended 30 September 2021: HK$80,039,000) and the weighted average of 1,918,625,000 ordinary shares (six months ended 30 September 2021: 1,915,677,000 shares) in issue during the period, calculated as follows:

	Six months ended 30 September	
	2022	2021
	'000	*'000*
Shares of the Company issued at the beginning of the period	**1,915,677**	1,915,677
Effect of shares of Share Award Scheme	**2,948**	–
Weighted average number of ordinary shares in issue during the period	**1,918,625**	1,915,677

(B) Diluted earnings per share

Diluted earnings per share for the six months ended 30 September 2022 and 2021 were the same as the basic earnings per share as there were no potentially dilutive ordinary share in existence during both periods.

9 DIVIDENDS

(A) Dividends payable to shareholders attributable to the reporting period

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
Interim dividend declared and paid after the Reporting Period of HK2.8 cents per share (six months ended 30 September 2021: HK1.2 cents per share)	**54,158**	23,211

The interim dividend has not been recognised as a liability at the end of the Reporting Period.

(B) Dividends payable to shareholders attributable to the previous financial year, approved and payable/paid during the reporting period

	Six months ended 30 September	
	2022	2021
	HK$'000	*HK$'000*
Final dividend in respect of the previous financial year, approved and payable during the following reporting period, of HK2.68 cents per share (six months ended 30 September 2021: HK1.5 cents per share, approved and paid during the following reporting period)	**51,837**	29,013
Less: Dividend of shares held by Share Award Scheme	**(839)**	(278)
	50,998	28,735

10 TRADE AND OTHER RECEIVABLES

As at the end of the reporting period, the ageing analysis of trade receivables (which are included in trade and other receivables) based on the invoice date and net of loss allowance, is as follows:

	As at 30 September 2022	As at 31 March 2022
	HK$'000	*HK$'000*
Less than 1 month	**186,053**	192,302
1 to 6 months	**58,559**	69,940
Over 6 months	**15,253**	46,701
Trade receivables	**259,865**	308,943
Other receivables	**5,803**	11,933
Deposits and prepayments	**49,960**	51,426
Amounts due from associates	**1,700**	1,739
Amounts due from joint ventures	**9,005**	6,505
	326,333	380,546

11 TRADE AND OTHER PAYABLES

As at the end of the reporting period, the ageing analysis of trade payables (which are included in trade and other payables), based on the invoice date, is as follows:

	As at 30 September 2022 *HK$'000*	As at 31 March 2022 *HK$'000*
Less than 1 month	**42,004**	31,317
1 to 6 months	**18,388**	18,909
Over 6 months	**193**	234
Trade payables	**60,585**	50,460
Salary and bonus payables	**55,532**	51,587
Payables and accruals for addition of property, plant and equipment	**38**	1,080
Other payables and accruals	**70,369**	50,544
Dividends payable	**50,998**	–
Receipt in advance	**3,943**	3,740
Amount due to a joint venture	**2,000**	2,000
	243,465	159,411

12 SHARE CAPITAL

	Number of shares *'000*	**Amount** *HK$'000*
Authorised:		
Ordinary shares of HK$0.01 each at 31 March 2022, 1 April 2022 and 30 September 2022	**5,000,000**	**50,000**
Issued:		
At 31 March 2022 and 1 April 2022	**1,915,677**	**19,157**
Shares held for Share Award Scheme *(Note)*	**(12,756)**	**(128)**
At 30 September 2022	**1,902,921**	**19,029**

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All ordinary shares rank equally with regard to the Company's residual assets.

Note: On 16 October 2018, the Share Award Scheme was adopted by the Company. Pursuant to the Share Award Scheme, the directors of the Company are authorised, at their discretion to determine individuals of any companies in the Group, for granting them the Company's shares. The Share Award Scheme will be valid and effective for a period of 10 years commencing from 16 October 2018.

The Company's shares to be granted under the Share Award Scheme will be purchased and held by a trustee. The maximum of purchases by the trustee in any financial year will be fixed by the Company's board of directors but such purchases will not result the trustee holding at any time more than 3% of the total issued shares of the Company.

In addition, unless approved by the Company's board of directors, no share award will be granted to any individual if granting of such share award would result in the total number of shares granted to the individual during any 12–month period exceeding 0.5% of the total issued shares of the Company (0.1% of the total issued shares of the Company in case for an independent non–executive director of the Company).

During the six months ended 30 September 2022, the Share Award Scheme acquired 22,756,000 shares through purchases on the open market. The total amount paid to acquire the shares during the period was approximately HK$19,486,000. During the six months ended 30 September 2021, the Share Award Scheme did not acquire any shares through purchases on the open market.

During the six months ended 30 September 2022, the Company has granted a total of 10,000,000 shares to eligible grantees, including certain directors of the Company and employees of the Group. There was no share award granted under the Share Award Scheme during the six months ended 30 September 2021.

Details of the shares awarded under the Share Award Scheme during the six months ended 30 September 2022 are as follows:

	Number of Shares					
Date of grant	**As at 1 April 2022**	**Granted during the period**	**Vested during the period**	**Lapsed during the period**	**As at 30 September 2022**	**Vesting period**
11 April 2022	–	10,000,000	(10,000,000)	–	–	31 May 2022

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

The epidemic situation in Hong Kong stabilised in the second quarter of 2022 following the fifth wave of outbreak at the beginning of the year. With the subsided COVID-19 infection cases, the HKSAR Government's relaxation of social distancing and travel restriction measures have gradually led to the rebound of economic and social activities. As a result, we have seen notable positive momentum in our performance in the first half of FY2023. Continued improvement is expected upon the trend of further easing of restrictive restrictions, driven by the gradual recovery of the overall economy alongside the boosting measures by the government.

Amid the market challenges, the Group remained resilient. Our first-half performance reflected the progress we have made with growth across the business segments, disciplined cost control and enhanced operational efficiency. We have committed to the consistent and careful execution of our strategies which, we believe, has positioned the Group well in navigating the challenges with resilience.

RESULTS

During the six months ended 30 September 2022, the Group posted a period-on-period growth of 8.9% in its total revenue, amounting to HK$817.4 million. Gross profit also increased by 24.8% to HK$340.4 million, whilst profit attributable to equity shareholders amounting to HK$136.2 million, up by HK$56.2 million or 70.2%, which was mainly contributed by the uplift in sales revenue, together with the enhancement in product mix and operating leverage, coupled with the subsidies from the HKSAR Government pertinent to the Employment Support Scheme.

The Group's subsidiary in consumer branded healthcare, JBM Healthcare (HKSE stock code: 2161), posted growth of 25.0% in sales revenue to HK$236.8 million during the Reporting Period, with profit attributable to equity shareholders up by 116.0% to HK$21.6 million, primarily attributed to the easing of social distancing measures in Hong Kong which buttressed retail spending sentiment and a gradual recovery of the overall sales, alongside with the sound progress on the cross-border e-commerce platform and the subsidies from the HKSAR Government pertinent to the Employment Support Scheme.

The Group continued to maintain a healthy financial position as supported by its strong cash flows, with adjusted EBITDA of HK$290.5 million for the Reporting Period and the net gearing ratio decreased significantly from 29.2% as at 31 March 2022 to 20.8% as at the end of the Reporting Period.

OPERATION PERFORMANCE

Resilient Performance in Generics

During the first half, the Generic Drugs business of the Group continued to demonstrate resilience and delivered growth of 3.5% to HK$581.9 million in sales revenue amid the challenges of COVID-19. This was driven by the stable growth in both the Private and Public Sectors. This overall growth was benefitted from the easing of social distancing measures which facilitated the resumption of medical consultation visits in both public and private sectors in Hong Kong, thus boosting the demand for essential drugs as well as specialty medicines for chronic diseases.

Robust Portfolio to Meet Public Demand

As a leading manufacturer of generics in Hong Kong, the Group carries a broad and targeted portfolio of essential and specialty drugs to serve the needs of medical professionals and patients.

Responding to the fifth COVID-19 outbreak in the first quarter of the year, the Group geared up its production and supply of symptomatic relief medications to meet the surged patient needs, which was reflected by the growth of 48.5% in the Group's range of cold and flu preparations in the Public Sector.

Exhibiting a robust trend, medications for the aging population and chronic disease patients continued to present a strong demand. Among the Group's cardiovascular offerings, the lipid-lowering product class recorded a notable growth of 42.6% with increased consumption of new products such as Rosuvastatin and Atorvastatin Tablets. In addition, the anti-anginal product class recorded sales growth by 30.0% during the Reporting Period due to the newly awarded public tender for Trimetazidine Modified Released Tablets.

Furthermore, therapeutic sectors of anti-depressants and gout preparations also exhibited positive growth of 13.6% and 13.7% respectively. During the Reporting Period, the Group also secured certain first-time public tenders, which included Enticavir Tablet, Ramipril Tablet, Solifenacin Tablet and Mycophenolate Infusion.

The Group's Angiotensin II receptor antagonists and lipid-lowering products in the cardiovascular product class also recorded a strong growth of 66.4% and 60.0% respectively in the Private Sector during the Reporting Period. Non-steroidal anti-inflammatory drug class, on the other hand, recorded a positive growth of 31.4%, mainly attributable to increased sales of new products such as Celecoxib Capsules and Etoricoxib Tablets.

New Product Introduction

As a continued effort to meet the medical and patient needs with quality generics, the Group launched a number of new products including Trimetazidine Modified Release Tablet, Olmesartan Tablets, Bicalutamide Tablet, Ofloxacin Ear Drop and Idarubicin Injection during the Reporting Period.

Additionally, the Group has secured registration approval for 21 new products for upcoming market launches.

R&D Pipeline on Track

Embedding a prudent and disciplined approach to R&D, we have made steady progress with our pipeline during the Reporting Period. A total of 16 products have completed the development process and have been submitted to the Department of Health of Hong Kong for registration approval.

As of 30 September 2022, there were 177 products in our pipeline, 59 items have been approved for registration, 14 of them have been submitted for registration, 48 items have finished the development stage and were under stability preparation or stability study, plus 27 items were currently under formulation or pre-formulation research development stage.

Increased Production to Meet Revived Demand

With the relaxation of social distancing measures by the HKSAR Government which facilitated consultation visits by patients to public and private hospitals and clinics, the Group benefited from the boosted demand for essential and specialty medicines during the Reporting Period.

The Group's overall output of liquid dosage forms increased to more than 969 thousand liters, growing by 93.2% over the same period of last year. This substantial increase was mainly due to the heightened demand for cold & flu medications with the easing of social distancing measures and an increase in retail off-take.

The production output of eye drop products also recorded a robust growth of 50.1% to more than 27 thousand liters, driven by the continuous optimisation of the production capacity of the sterile preparation line and the integration of new products from the Group's R&D pipeline.

With the operation of the new oral solid production line in place, the total manufacturing output of our solid preparations reached more than 1.754 billion capsules and tablets during the Reporting Period, offering a 14.7% increase over the same period of last year.

In addition, the semi-solid dosage output of the Group totaled around 175.6 tonnes, with an increase of 13.0% from the same period of last year.

To cater to the increasing market demand, the Group has been undertaking various plant expansion projects and equipment upgrade plans aimed at the continuous enhancement of the Group's production capacity and capability in the coming years.

BUSINESS DEVELOPMENT

In-license of Specialised Products

The Group continued to supplement its R&D pipeline and broaden its portfolio of difficult-to-make specialty drugs through in-licensing collaborations with reputable branded manufacturers worldwide.

During the Reporting Period, we have signed exclusive in-license agreements for an additional 27 targeted specialty drugs covering classes of the central nervous system (CNS), immunomodulatory, chemotherapy, and anti-cancer drugs, as well as medications used as an immunosuppressant for organ transplants and as a treatment for renal cell cancer and other tumors. Among them, 15 are injectable items, 6 are oral dosages, and 6 are classified as topical medication.

We are also actively exploring collaboration with a reputable partner for a number of new chemical entity (NCE) drugs to be distributed and marketed in Hong Kong and Macau.

Making Inroads into The Greater Bay Area ("GBA")

The Group's collaboration with the University of Hong Kong-Shenzhen Hospital in introducing its oral solution treatment for acute promyelocytic leukemia, Arsenic Trioxide Oral Solution, into designated hospitals in the GBA has been given approval by Guangdong Province Medical Product Administration. This marked the first Hong Kong-made specialty medicine being approved under the "Interim Regulations on the Administration for Importing Urgently Needed Clinical Drugs and Medical Devices from Hong Kong and Macao to the Guangdong-Hong Kong-Macao Greater Bay Area of Guangdong Province".

Under the scheme, designated and approved healthcare institutions operating in the GBA are allowed to use Hong Kong-registered drugs and medical devices used in Hong Kong public hospitals for urgent clinical use. This is a facilitation measure for Hong Kong residents working and living in the GBA seeking healthcare services and will help attract local and multinational pharmaceutical, biomedical, and health technology companies to expand their businesses and benefit patients in the GBA.

The Group is the sole manufacturer of the innovative drug Arsenic Trioxide Oral Solution (Arsenol) in Hong Kong. In addition to its introduction into the GBA, the Group has expanded its market to other Southeast Asia regions, such as Macau, Singapore and Malaysia, offering a clinically established life-changing medication to patients who suffer from acute promyelocytic leukemia.

SUSTAINABILITY

We believe that the success and sustainable growth of the Group are closely tied to that of the communities we serve. It goes beyond simply business but also the societal benefits that it brings along.

As a company that attaches long-term commitment to environmental, social and governance (“**ESG**”) duties, we have formulated and progressed on our ESG strategy, “Jacobson 5 to Thrive”, which underpins five priority areas, namely, product responsibility, commitment to employees, environmental stewardship, societal engagement and corporate governance duty. Each core component is a reflection of how we respond to the 17 Sustainable Development Goals (SDGs), which were created by the United Nations in 2015.

In response to our ESG strategy, we have set key performance indicators (KPIs) and will continue to evaluate additional goals to track our progress on priority issues and programs, including greenhouse gas emissions, water and electricity usage, as well as utilisation of renewable energy.

As a pharmaceutical company that is deep-rooted in Hong Kong, we will continue to expand our role as an integral part of Hong Kong’s healthcare system. We will embed our sustainability values as a core part of our strategy to develop a more resilient and successful business now and in the future.

OUTLOOK

As much as the waves of the epidemic have impacted life and the economy in Hong Kong, we have seen gratifying signs of the stabilisation of the epidemic situation with an increasing vaccination level among the public. The expectation of the gradual easing of restrictions, alongside the HKSAR Government’s economic boosting measures including successive payout of consumption vouchers and relaunch of the employer support scheme, we believe, will help lift business and consumer sentiments. We have reasons to be cautiously positive to foresee the continual improvements in Hong Kong’s economy buttressed by its strong fundamentals.

Albeit the COVID-19 impact has been on business performance, we believe it will be transient. We remain positive about the future outlook for the healthcare industry and the growth impetus of the generic drugs market. Growth factors, such as increased government healthcare investment and generics substitution policy, aging population, the prevalence of chronic diseases and increased demand for better healthcare, will continue to be key growth drivers for both essential and specialty medicines.

To capitalise on the prospect, we will stay focused on advancing our growth strategies and well-positioning ourselves as an eminent provider of essential medicines and specialty drugs in Hong Kong and Asia. To further strengthen our market position, our strategic priorities will center on maximising the commercial opportunities of our portfolio of offerings, strengthening our product pipelines through in-licensing and in-house R&D, building a sound commercial platform on marketing and regulatory affairs management to forge collaboration with regional and international partners, and expanding our presence in strategic markets in Asia.

Looking forward, our business strategy remains robust and resilient. We will continue to aim to deliver solid performance, achieve sustainable growth and increase shareholder return while maintaining a healthy financial position.

REMUNERATION POLICY

As of 30 September 2022, the Group has a total of 1,801 employees (compared to 1,723 employees as of 30 September 2021). For the Reporting Period, the total staff cost of the Group was HK$216.4 million, compared to HK$202.9 million for the six months ended 30 September 2021 with the corresponding enhancement in staff deployment supporting the operation and development of the Group. All of the Group's employees have entered into standard employment contracts with the Group. Remuneration packages for the Group's employees in general comprise one or more of the following elements: basic salary, sales-related incentives, productivity-related incentives and work performance bonuses. The Group sets out performance attributes for its employees based on their positions and job functions. It periodically reviews their work performance against the Group's strategic objectives and targets. The results of such reviews are taken into consideration when assessing salary adjustments, bonus awards, promotions, staff development plans and training needs. The Group provides various benefit schemes to its employees including annual leave entitlement, mandatory provident fund, group medical insurance and life insurance. A workers union has been established for the Group's employees in China according to local labour laws. As of 30 September 2022, the Group has not experienced any strikes or any labour disputes with its employees which would likely have had a material impact on its business.

The Group places a high value on recruiting, developing and retaining its employees. It maintains high recruitment standards and provides competitive compensation and benefit packages to attract and retain talents. The Group also emphasises on training and developing employees. In addition to different skill and knowledge based in-house training programs, the Group has training sponsorship policy to encourage its employees to attend external training to enhance their job competencies.

FINANCIAL REVIEW

REVENUE

Revenue by Operating Segments

FY2023 Interim



FY2022 Interim



The increase in revenue of HK$67.0 million or 8.9% compared to FY2022 Interim was contributed by the increase in revenue of HK$19.7 million or 3.5% in the generic drugs segment and HK$47.3 million or 25.1% in the branded healthcare segment. The revenue split of the two segments was at the ratio of 71% and 29%.

In the generic drugs segment, with the continuous relief of pandemic-control measures and gradual recovery of social activities, medical consultation visits in the Public and Private Sectors began to resume, thus boosting the demand for essential drugs as well as specialty medicines. In addition, newly awarded public tenders, alongside increasing demand for medications driven by the ageing population and prevalence of chronic diseases also contributed to the stable sales growth of the Public Sector.

In the branded healthcare segment, the easing of social distancing polices in Hong Kong, which buttressed retail spending sentiment, resulted in a substantial increase in revenue during the Reporting Period. Some of our notable branded products, such as Po Chai Pills, AIM Atropine Eye Drops and Oncotype DX Breast Cancer Recurrence Score Test, continued to contribute a stable growth during the Reporting Period. In addition, we have been making sound progress on our cross-border e-commerce platform, which provides a fast expanding avenue for reaching out to those target prospects in the Mainland China market.

Revenue by Geographic Locations





Hong Kong continued to be the major revenue stream, representing 87% of the total revenue with an increase of HK$35.1 million compared to FY2022 Interim buttressed by stable growth of the generic drugs business in both Private and Public Sectors during the Reporting Period alongside the stabilisation of COVID-19 pandemic in Hong Kong. The revenue in Mainland China increased by HK$39.5 million, mainly due to the significant increase in sales via various cross-border e-commerce platforms during the Reporting Period. The revenue decrease in Macau by HK$11.6 million was mainly resulted from the travel restriction measures in Macau during the Reporting Period. The revenue from other overseas markets increased slightly by HK$4.0 million which was mainly contributed by the new sales in the USA during the Reporting Period.

COST OF SALES





The slight decrease in total cost of sales of HK$0.7 million or 0.1% was mainly driven by the decrease in material cost during the Reporting Period. Material cost continued to be the major component contributing approximately 49% of the total cost of sales, while staff cost and other production cost contributed to 28% and 23% respectively.

The decrease in material cost of HK$11.1 million or 4.5% was attributable to the change in sales mix as well as continual optimisation of our manufacturing process and product formulation resulting in the decrease in indirect materials and other manufacturing overheads during the Reporting Period.

The increase in staff cost of HK$9.3 million or 7.5% reflected the increase in number of production headcount during the Reporting Period primarily due to the increase in production volume to support the sales growth while the increase in other production cost of HK$1.1 million or 1.0% was generally in line with the overall sales trend of the Group.

PROFIT FROM OPERATIONS



The profit from operations increased significantly by HK$84.1 million or 71.9% to HK$201.0 million. The enhancement in the profit from operations was principally contributed by the increase in gross profit of HK$67.6 million as a result of the uplifted sales demand owing to the stabilisation of the COVID-19 pandemic in Hong Kong, together with an improvement in sale prices, product mix and operating leverage. The increase in other net income of HK$22.4 million also contributed to the increase in the profit from operations, which was mainly due to the increase in the net distribution and logistics service income and the one-off Employment Support Scheme subsidy from the Hong Kong Government recognised during the Reporting Period.

FINANCE COSTS

The increase in finance costs was mainly attributable to the higher bank loan balance as a result of the syndicated loan obtained, as well as the raising interest rates, during the Reporting Period.

INCOME TAX

The increase in income tax primarily reflected the higher profit from operations during the Reporting Period compared to FY2022 Interim after excluding the non-taxable one-off Employment Support Scheme subsidy from the Hong Kong Government recognised during the Reporting Period.

PROFIT FOR THE PERIOD



The profit for the period increased significantly by HK$64.5 million or 77.8% to HK$147.4 million, which reflected the increase in profit from operations during the Reporting Period, offset partially by the additional finance costs and income tax.

ASSETS

Property, plant and equipment

The decrease in property, plant and equipment principally reflected the depreciation of HK$70.9 million, which was offset partially by the additions of HK$33.7 million mainly arose from the acquisitions of properties, plant and machinery used by our pharmaceutical manufacturing plants.

Intangible assets

The decrease in intangible assets was primarily attributable to the amortisation of HK$21.8 million.

Inventories

The increase in inventories by HK$62.4 million or 19.8% was mainly resulted from the resumption of the production level as a result of the stabilisation of COVID-19 pandemic in Hong Kong during the Reporting Period.

Cash and cash equivalents

As at 30 September 2022, approximately 97.2% of cash and cash equivalents were denominated in Hong Kong dollars (as at 31 March 2022: 93.5%), while the remaining balances were denominated in Euros, United Stated dollars, Renminbi, Taiwan dollars, Singapore dollars and Macau pataca.

LIABILITIES

Bank loans

The increase in bank loans as at 30 September 2022 was mainly attributable to the syndicated loan obtained during the Reporting Period for refinancing the existing bank loans which bear variable interest. As at 30 September 2022, all bank loans of the Group were denominated in Hong Kong dollars.

USE OF PROCEEDS

IPO proceeds

Net proceeds of HK$695,540,000 were raised from the initial public offering of the Company (included proceeds from the over-allotment option exercised by the underwriter amounted to HK$98,438,000 and after the deduction of underwriting fees, commissions and expenses paid by the Company in connection with the initial public offering) (the "**IPO Proceeds**").

The table below sets forth the status of utilisation of the IPO Proceeds as at 31 March 2022 and 30 September 2022 respectively, and the expected timeline of the use of the unutilised IPO Proceeds:

		As at 31 March 2022		**As at 30 September 2022**		**Expected timeline for utilising the remaining IPO Proceeds**
Use of IPO Proceeds	**Proposed application***	Actual utilised amount	Unutilised amount	**Actual utilised amount**	**Unutilised amount**	
	HK$'000	*HK$'000*	*HK$'000*	***HK$'000***	***HK$'000***	
Acquisitions – Expansion of businesses in generic drugs and proprietary medicines	139,108	139,108	–	**139,108**	**–**	N/A
Acquisitions – Enhancement of distribution network	104,331	104,331	–	**104,331**	**–**	N/A
Acquisitions – Intangible assets	69,554	69,554	–	**69,554**	**–**	N/A
Capital investments – Upgrading of manufacturing plants and facilities	113,197	113,197	–	**113,197**	**–**	N/A
Capital investments – Two specific automated production facilities	12,000	12,000	–	**12,000**	**–**	N/A
Expansion of bioequivalence clinical studies	98,449	78,001	20,448	**80,900**	**17,549**	On or before 31 March 2025
Establishment of a new joint R&D centre with HKIB	5,882	5,882	–	**5,882**	**–**	N/A
Marketing and advertising	83,465	83,465	–	**83,465**	**–**	N/A
General working capital	69,554	69,554	–	**69,554**	**–**	N/A
Total	695,540	675,092	20,448	**677,991**	**17,549**	

* The Company has published an announcement on 9 March 2022 relating to the change of allocation of the unutilised IPO Proceeds and the expected timeline of full utilisation by (a) reallocating approximately HK$4.1 million which was originally allocated for establishment of a new joint R&D centre with HKIB to expansion of bioequivalence clinical studies; and (b) extending the expected timeline of the use of the unutilised IPO Proceeds from 31 March 2023 to 31 March 2025.

The Group intends to apply the remaining IPO Proceeds according to the revised plans disclosed in the announcement published on 9 March 2022 as shown above.

LIQUIDITY, CAPITAL RESOURCES AND CAPITAL STRUCTURE

The Group consistently adheres to conservative fund management. The solid capital structure and financial strength continue to provide a solid foundation for the Group's future business development as well as mergers and acquisitions.

The Group's primary uses of cash are to fund working capital, capital expenditures and mergers and acquisitions. During the Reporting Period, the Group funded its cash requirements principally from cash generated from operations and bank borrowings.

CHARGE ON GROUP ASSETS

The carrying value of assets pledged against bank loans decreased from HK$495.7 million as at 31 March 2022 to HK$75.2 million as at 30 September 2022 which was mainly attributable to the release of pledged assets for bank loans refinanced by the syndicated loan of HK$1.4 billion during the Reporting Period.

NET GEARING RATIO

The net gearing ratio of the Group (bank loans less cash and cash equivalents, divided by total equity multiplied by 100%) decreased from 29.2% as of 31 March 2022 to 20.8% as of 30 September 2022, mainly attributable to net cash generated from operating activities during the Reporting Period of HK$308.0 million.

FINANCIAL RISK ANALYSIS

Management considered that the Group did not have significant exposure to fluctuation in exchange rates and any related hedges.

CONTINGENT LIABILITIES

As of 30 September 2022, the Group did not have any significant contingent liabilities.

SIGNIFICANT INVESTMENT HELD, MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group had no material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period. The Group had no individually significant investments held during the Reporting Period.

NON-ADJUSTING EVENTS AFTER THE REPORTING PERIOD

No significant event has taken place subsequent to 30 September 2022 and up to the date of this interim results announcement.

PRINCIPAL RISKS AND UNCERTAINTIES

The following is a summary of the principal risks and uncertainties identified by the Company which may have material and adverse impact on its business or operation, and how the Company endeavours to manage the risks involved. There may be other principal risks and uncertainties in addition to those shown below which are not known to the Company or which may not be material now but could turn out to be material in the future.

– The Group operates in pharmaceutical manufacturing industry and is subject to various regulations; failure to comply with pharmaceutical or other regulations may restrict our business operations. The Group has dedicated quality control and quality assurance team in each manufacturing plant to ensure compliance with relevant regulations.

– The Group made a number of successful acquisitions; however, the Group may not be able to successfully identify, consummate and integrate future mergers or acquisitions. The Group will continue to seek for new acquisition opportunities and perform adequate due diligence to assess the potential acquisition targets.

– The Group operates in generic drugs business and development of new products provides additional growth driver for the Group. However, we may not be able to develop and launch new product according to our schedule. The Group continues to invest in the R&D of new products and engage external experts to enhance our overall R&D capability.

– The Group is also exposed to risks of liability and loss due to defective products as well as damage to the Group's reputation. While the Group has taken out product liability insurance, the insured amount may not be sufficient to cover all damages claimed. The Group has a designated production and quality assurance team to monitor product quality in each manufacturing plant to ensure they are in compliance with respective specifications.

The Company believes that risk management is essential to the Group's efficient and effective operation. The Company's management assists the Board in evaluating material risk exposure in the Group's business, participating in formulating appropriate risk management and internal control measures, and ensuring its implementation in the daily operational management.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Group is primarily engaged in the development, production, marketing and sale of generic drugs and branded healthcare products, a line of business that does not have any material impact on the environment. The key environmental impact from the Group's operation is related to electricity, water and paper consumption. The Group is fully aware of the importance of sustainable environmental development, and has implemented a number of measures to encourage environmental protection and energy conservation.

During the Reporting Period, there was no significant regulatory non-compliance with applicable environmental laws and regulations.

COMPLIANCE WITH LAWS AND REGULATIONS

During the Reporting Period, the Group was in compliance with the applicable laws and regulations which have significant impacts on the Group in all material respects.

CORPORATE GOVERNANCE HIGHLIGHTS

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as its own code of corporate governance.

During the Reporting Period, the Company has complied with all the code provisions of the CG Code and adopted most of the best practices set out therein, except for the following provision:

Code provision C.2.1 of the CG Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing.

Currently, Mr. Sum is the chairman of the Board and the chief executive officer of the Company and accordingly, there is no written terms setting out the division of responsibilities between the chairman and chief executive. The Board considers that Mr. Sum is the founder of the Group and had been managing the Group's business and overall strategic planning since its establishment, the vesting of the roles of chairman and chief executive officer in Mr. Sum is beneficial to the business prospects and management of the Group by ensuring consistent leadership within the Group and enabling more effective and efficient overall strategic planning for the Group. The Board also considers that the balance of power and authority of the Board for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively.

The Board will continue to review and consider splitting the roles of chairman of the Board and the chief executive officer of the Company at an appropriate time, taking into account the circumstances of the Group as a whole.

AMENDMENTS TO MEMORANDUM AND ARTICLES OF ASSOCIATION

At the annual general meeting of the Company held on 23 September 2022, the shareholders of the Company passed a special resolution in relation to the proposed amendments to the amended and restated memorandum and articles of association of the Company and the adoption of the second amended and restated memorandum and articles of association of the Company. For further details, please refer to the Company's circular dated 28 July 2022.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding securities transactions of the Directors. Having made specific enquiry with the Directors, all Directors confirmed that they have complied with the required standard as set out in the Model Code throughout the Reporting Period.

AUDIT COMMITTEE

The Board has established an audit committee (the "**Audit Committee**") which comprises three independent non-executive Directors, namely Mr. Young Chun Man, Kenneth (Chairman), Dr. Lam Kwing Tong, Alan and Professor Lam Sing Kwong, Simon. The primary duties of the Audit Committee include reviewing and supervising the Group's financial reporting process, internal control and risk management systems, preparing financial statements and internal control procedures. It also acts as an important link between the Board and the external auditor in matters within the scope of the group audit.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor its subsidiaries has purchased, sold or redeemed any of the Company's listed securities throughout the Reporting Period.

REVIEW OF INTERIM RESULTS

The interim results for the six months ended 30 September 2022 are unaudited, but have been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the 2022 Interim Report to be sent to shareholders of the Company.

The Audit Committee, together with management of the Company, has also reviewed the interim results for the six months ended 30 September 2022.

INTERIM DIVIDEND

The Board declared the payment of an interim dividend per ordinary share for the six months ended 30 September 2022 of HK2.8 cents for the total amount of approximately HK$54.2 million (six months ended 30 September 2021: HK1.2 cents). The interim dividend will be paid on 29 December 2022 (Thursday) to shareholders whose names appear on the register of members of the Company on 13 December 2022 (Tuesday), the record date. The details of interim dividend of the Group are set out in note 9 to this interim results announcement.

CLOSURE OF REGISTER OF MEMBERS

In order to determine the entitlement of shareholders of the Company to receive the interim dividend, the register of members of the Company will be closed from 12 December 2022 (Monday) to 13 December 2022 (Tuesday), both days inclusive, during which period no transfer of shares of the Company will be registered. All transfer documents, accompanied by the relevant share certificates, shall be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on 9 December 2022 (Friday).

PUBLICATION OF THIS INTERIM RESULTS ANNOUNCEMENT AND THE 2022 INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and of the Company (www.jacobsonpharma.com). The 2022 Interim Report containing all the information required by the Listing Rules will be published on the respective websites of the Stock Exchange and the Company and will be dispatched to the shareholders of the Company in due course.

By order of the Board
Jacobson Pharma Corporation Limited
YIM Chun Leung
Executive Director

Hong Kong, 25 November 2022

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.

GLOSSARY

In this announcement, unless otherwise specified, the following glossary applies:

"2022 Interim Report"	the interim report of the Company for the six months ended 30 September 2022
"AIM Atropine Eye Drops"	refers to AIM Atropine 0.01% Eye Drops, AIM Atropine 0.05% Eye Drops and AIM Atropine 0.125% Eye Drops procured from Aseptic Innovative Medicine Co. Ltd., an anticholinergic agent as a sterile topical preservative-free ophthalmic solution that is commonly used in the treatment of myopia, mydriasis and cycloplegia
"Board"	the board of directors of the Company
"CG Code"	Corporate Governance Code as amended or supplemented from time to time contained in Appendix 14 to the Listing Rules
"China", "Mainland China"or "the PRC"	the People's Republic of China excluding, for the purpose of this interim results announcement, Hong Kong, Macau and Taiwan
"Company", "our Company" or "the Company"	Jacobson Pharma Corporation Limited, an exempted company incorporated in the Cayman Islands with limited liability on 16 February 2016
"COVID-19"	Coronavirus disease 2019
"Director(s)"	the director(s) of the Company
"FY2022"	the year ended 31 March 2022
"FY2022 Interim"	the six months ended 30 September 2021
"FY2023"	the year ending 31 March 2023
"FY2023 Interim" or "Reporting Period"	the six months ended 30 September 2022
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"HKIB"	The Hong Kong Institute of Biotechnology
"Hong Kong" or "HKSAR"	the Hong Kong Special Administrative Region of the PRC

"Jacobson", "Group", "our Group", "the Group", "we", "us" or "our"	the Company and its subsidiaries and, in respect of the period before we became the holding company of our present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)
"JBM Healthcare"	JBM (Healthcare) Limited, an exempted company incorporated in the Cayman Islands with limited liability on 7 January 2020, the issued shares of which are listed on the Main Board on 5 February 2021, an indirect non-wholly owned subsidiary of the Company (stock code: 2161)
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Macau"	the Macau Special Administrative Region of the PRC
"Main Board"	Main Board of the Stock Exchange
"Model Code"	Model Code for Securities Transaction by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules
"Mr. Sum"	Mr. Sum Kwong Yip, Derek, our chairman, executive Director, chief executive officer and one of our controlling shareholders
"Private Sector"	refers to non-Public Sector
"Public Sector"	refers to public sector institutions and clinics in Hong Kong
"R&D"	research and development
"Share Award Scheme"	the share award scheme adopted by our Company on 16 October 2018, the principal terms of which are summarised in the announcement of the Company dated 16 October 2018
"Stock Exchange"	The Stock Exchange of Hong Kong Limited